CompletedEarly Phase 1

Recombinant Human Fibroblast Growth Factor-2 (rhFGF-2) In Gingival Recession Defects

India30 participantsStarted 2019-05-01

Plain-language summary

This study was a single-arm trial to obtain preliminary data on the efficacy of collagen membranes impregnated with recombinant human fibroblast growth factor (rhFGF-2) in the treatment of Miller's class I and class II gingival recessions.

Who can participate

Age range20 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * systemically healthy subjects between 20-55 years presenting with Miller's class I or class II gingival recession\[ Exclusion Criteria: * 1\. Recessions associated with root demineralization/caries, deep cervical abrasion or pulpal pathology, 2. Patients with history of systemic conditions affecting periodontium and, 3. Smokers.

What they're measuring

Width of keratinized gingiva (wKG)

Timeframe: 5 months

Trial details

NCT IDNCT04361630

SponsorSVS Institute of Dental Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-11-01

View on ClinicalTrials.gov More Periodontitis trials